N/A N=10 On-pump Intraoperative Echocardiography
Septal Myectomy
Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=215 Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead
Ventricular Tachycardia · Ventricular Fibrillation
Primary: Implant Success Rate at Septal Site — 97; 99 Participants
N/A N=140 A New Operation for the Treatment for Long-standing Atrial Fibrillation
Cardiovascular Disease
Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants
Phase 3 N=112 A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
HOCM, Hypertrophic Obstructive Cardiomyopathy
Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001
N/A N=20 A Pilot Study of Interventricular Septal Puncture for Cardiac Resynchronization Therapy to Treat Heart Failure
Heart Failure
Primary: Number of Participants Free of Adverse Effects at 6 Months Post Procedure — 15 Participants
N/A N=26 Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
Atrial Fibrillation
Primary: Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer. — 3 Participants
N/A N=70 The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)
Nasal Obstruction
Primary: Nasal Obstruction Symptom Evaluation (NOSE) Scale Mean Change — -45.3 score on a scale
N/A N=91 Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder
Heart Septal Defects, Ventricular
Primary: Closure of Muscular Ventricular Septal Defects — 91 participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=60 Prophylactic Maze to Prevent Atrial Fibrillation in Adult Cardiac Surgery
Coronary Artery Disease
Primary: Incidence of Documented Post-operative Atrial Fibrillation — 17; 2 Participants
Phase 3 N=75 Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…
N/A N=92 Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
Ventricular Septal Defects
Primary: Primary Effectiveness End Point: Technical Success — 75 Participants
Phase 2 N=260 Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery
Atrial Fibrillation · Mitral Valve Insufficiency · Mitral Valve Stenosis
Primary: Freedom From Atrial Fibrillation — 31.1; 61.8 percentage of patients
N/A N=12 Atrial Deganglionation as a Therapy for Cardiac Surgery Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: The Number of Patients in Sinus Rhythm at 12 Months. — 12 Participants
Phase 3 N=2,136 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
Cardiovascular Diseases · Coronary Disease · Heart Failure, Congestive
Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12
Phase 3 N=75 Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…
Phase 2 N=21 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
N/A N=439 Evaluation Of New Onset Postoperative Atrial Fibrillation
Atrial Fibrillation New Onset
Primary: Primary Safety Endpoint — 3.9; 3.6 percentage of participants
N/A N=208 Minimally Invasive or Conventional Edge-To-Edge Repair for Severe Mitral Regurgitation Due to Bileaflet Prolapse in Barlow's Disease: Does the Surgical Approach Have an Impact on the Long-term Results?
Barlow's Disease · Prolapse; Mitral
Primary: Cardiac Death — 3.9; 3.8 percentage of participants with event
N/A N=16 Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty
Nasal Obstruction
Primary: Operative Time — 35; 423 seconds
N/A N=40 Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium
Atrial Fibrillation
Primary: Left Atrial (LA) Remodeling Pre-ablation — 2; 31; 7; 0 participants — p=0.48
Phase 2 N=70 AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Left Atrial Appendage Exclusion
Primary: Rate of Device Related Serious Adverse Events — 0 Number of participants
N/A N=51 MitraClip China PMS
Mitral Regurgitation
Primary: Percentage of Participants With Acute Procedural Success (APS) — 93.9 percentage of participants
Phase 3 N=251 Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
N/A N=24 Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF
Atrial Fibrillation
Primary: Number of Participants With Device-related Primary Safety Adverse Events — 0 Participants
Phase 4 N=30 Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Coronary Artery Disease
Primary: Myocardial Defect Perfusion — 15.76; 15.38; 2.08; 3.85 Percentage of Myocardial Perfusion
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=61 Cardioband With Transfemoral Delivery System
Mitral Regurgitation
Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants